John Jenco’s Post

Malarial parasitemia in pregnancy is estimated to cause up to 50,000 maternal deaths and 200,000 stillbirths in Africa each year. Two NIH-supported trials of an experimental malaria vaccine found that all three tested regimens were safe in healthy Malian adults. Read more about this study: https://bit.ly/4dD2bD6 #malaria #parasites #vaccine #MalariaVaccine #ClinicalTrial #trial #research #science #NIAID #NIH

Revolutionary Study Aims to Transform Malaria Treatment in Early Pregnancy

The Zika threat continues to expand its reach as the factors which drive transmission march along. If we do not prioritize the strategic expansion and modernization of global biosurveillance networks, apply modern data analytic capabilities and scale, and continue the development of diverse and complementary countermeasures, it is feasible the 2015-2016 public health disaster in Latin America could repeat itself.

📢 Original Article Sharing-Vol. 51 No. 1 💕 Title: Obstetric Outcomes during COVID-19 Pandemic: Vaccination and Infection in Pregnancy 🤵 Authors: Merve Dizdar,*, Aysegul Cakmak, Isil A. Ucar, Zeynep Senturk, Sumeyye Cimenli, Ecem Yuksel, Ceylan Kirmaci, Ibrahim Kale, Murat Muhcu 🔔 Full Text: https://lnkd.in/gkiWp5i3 🔑 Keywords: COVID-19; inactivated vaccine; mRNA vaccines; pregnancy outcome; safety; SARS-CoV-2 😎Welcome to your reading! #OBGYN #WomensHealth #Gynecology #WomensWellness #ReproductiveHealth #MaternalHealth #GynecologicalCancer #Oncology #OvarianTumor #SurgicalOncology #clinicalresearch

https://lnkd.in/deubwspj 🦠 Mpox in Pregnancy — Risks, Vertical Transmission, Prevention, and Treatment 👩⚕️ Key Points: • Mpox poses serious risks during pregnancy, including miscarriage, stillbirth, and maternal death. • Vertical transmission of the virus is possible, as shown in both human and animal studies. 💉 Vaccines: • Two smallpox vaccines, MVA-BN and LC16m8, are recommended for mpox prevention. • Tecovirimat is used under expanded access for treating severe mpox in pregnant and breast-feeding women. 🔑 Conclusion: Given the serious risks of mpox in pregnancy, further research is urgently needed to inform clinical guidelines and public health policies. Vaccination and treatment options are critical, but more data on their safety during pregnancy are essential. 📖 Full article: https://lnkd.in/deubwspj @The_NEJM

Zika virus: are we getting closer to a vaccine ? And could selectively protect pregnancies from the terrible aftermath on unborn babies. This primate pregnancy trial did show that such approach could prove highly efficacious . Vaccination during pregnancy elicited virus-neutralizing antibody responses that were comparable to those elicited by pre-pregnancy vaccination. Vaccination also reduced placental pathology, viral burden and vertical transmission of ZIKV during pregnancy, without causing adverse effects. These results provide key insights into the safety and efficacy of ZPIV vaccination during pregnancy and demonstrate positive effects of vaccination on the reduction of ZIKV infection, an important advance in preparedness for future ZIKV outbreaks. https://lnkd.in/ePdwCh8u

How comfortable are you with counseling pregnant patients about measles (aka Reubeola)? If you are like me, you have probably never seen a case of measles in clinical practice. Sadly, poor vaccine uptake and utilization of good public health measures make it likely we will be seeing more cases. QUICK FACTS: -Transmission: Measles is one of the world's most contagious diseases, spread by contact with infected nasal or throat secretions (coughing or sneezing) or breathing the air that was breathed by someone with measles -Prevention: if your patient is not previously vaccinated with the MMR vaccine, immunity can be determined by serum IgG testing. Pregnant patients cannot receive the MMR vaccine as it is a live, attenuated virus vaccine. BUT, patients can be vaccinated in the postpartum period prior to discharge home. -Incubation period 11-12 day -Prodromal symptom: fever, cough, coryza (runny nose), conjunctivitis (red, swollen eyes) -Maculopapular rash (flat and raised lesions) starts on head/face then spreads down to body and Koplik spots (tiny white spots inside the mouth) follow the prodromal symptoms by 2-4 days -Diagnosis: detection of measles-specific IgM antibody in serum and measles RNA by real-time polymerase chain reaction (RT-PCR) in a respiratory specimen are the most common methods for confirming measles infection Pregnancy risks: Measles is not teratogenic but can increase risk of preterm labor, low-birth weight, or miscarriage as well as medical complications like pneumonia or meningitis. Treatment: There is no antiviral treatment for measles and treatment is largely supportive. Pregnant patients without immunity who are exposed to measles might be candidates to receive intravenous immune globulin within 6 days of exposure. Please repost or reshare with anyone involved in prenatal care to help increase awareness.

On International Women’s Day, Medicines for Malaria Venture’s Wiweka Kaszubska, PhD and André Tchouatieu MD want to #InspireInclusion with a discussion on how clinical research can help protect pregnant women from malaria.  Malaria in pregnancy (MiP) is particularly dangerous to both mother and baby, and requires tailored preventive and treatment medicines. Though the World Health Organization strongly recommends the artemisinin-based combination therapy (ACT) artemether-lumefantrine to treat malaria during the first trimester of pregnancy, it only recommends one drug, sulfadoxine-pyrimethamine (SP), for intermittent preventive treatment of malaria in pregnancy (IPTp), which is contraindicated for use in the first trimester. Historically, pregnant women have been excluded from clinical trials for fear of causing harm, leading to pregnant patients routinely receiving therapies that have not been adequately studied in pregnancy. Excluding pregnant women from clinical research in this way puts them at greater risk of adverse effects in the real world due to the lack of evidence on how they can safely use medicines.   Read “Opinion: Clinical research must include pregnant women” in Devex to learn how clinical research must prioritize finding new tools to protect and treat pregnant women at risk of malaria. bit.ly/MMV_IWD24 #IWD2024

📃Scientific paper: Motivational Interviewing for Maternal Immunisation (MI4MI) study: a protocol for an implementation study of a clinician vaccine communication intervention for prenatal care settings Abstract: INTRODUCTION: Vaccination against influenza and pertussis in pregnancy offers a ‘two-for-one’ opportunity to protect mother and child. Pregnant patients have increased risk of severe disease from influenza and newborns have increased risk of severe disease from both influenza and pertussis. Obstetricians need communication tools to support their self-efficacy and effectiveness in communicating the importance of immunisation during pregnancy and ultimately improving maternal vaccination rates. METHODS AND ANALYSIS: We describe the protocol for a pragmatic study testing the feasibility and potential impact of a clinician communication strategy on maternal vaccination uptake. This study will be conducted in five prenatal care settings in Colorado, USA. The Motivational Interviewing for Maternal Immunisation strategy involves training prenatal care providers to use motivational interviewing in the vaccine conversation with pregnant patients. Our primary outcomes will be the adoption and implementation of the intervention measured using the Enhanced RE-AIM/Practical Robust Implementation and Sustainability Model for dissemination and implementation. Secondary outcomes will include provider time spent, fidelity to Motivational Interviewing and self-efficacy measured through audio recorded visits and provider surveys, patients’ visit experience based on audio recorded visits and follow-up interviews, and maternal vaccine uptake as measured through chart reviews. ETHICS AND... Continued on ES/IODE ➡️ https://etcse.fr/PQKG ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Motivational Interviewing for Maternal Immunisation (MI4MI) study: a protocol for an implementation study of a clinician vaccine communication intervention for prenatal care settings Abstract: INTRODUCTION: Vaccination against influenza and pertussis in pregnancy offers a ‘two-for-one’ opportunity to protect mother and child. Pregnant patients have increased risk of severe disease from influenza and newborns have increased risk of severe disease from both influenza and pertussis. Obstetricians need communication tools to support their self-efficacy and effectiveness in communicating the importance of immunisation during pregnancy and ultimately improving maternal vaccination rates. METHODS AND ANALYSIS: We describe the protocol for a pragmatic study testing the feasibility and potential impact of a clinician communication strategy on maternal vaccination uptake. This study will be conducted in five prenatal care settings in Colorado, USA. The Motivational Interviewing for Maternal Immunisation strategy involves training prenatal care providers to use motivational interviewing in the vaccine conversation with pregnant patients. Our primary outcomes will be the adoption and implementation of the intervention measured using the Enhanced RE-AIM/Practical Robust Implementation and Sustainability Model for dissemination and implementation. Secondary outcomes will include provider time spent, fidelity to Motivational Interviewing and self-efficacy measured through audio recorded visits and provider surveys, patients’ visit experience based on audio recorded visits and follow-up interviews, and maternal vaccine uptake as measured through chart reviews. ETHICS AND... Continued on ES/IODE ➡️ https://etcse.fr/PQKG ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.